SK Life Science’s newly approved treatment for partial-onset seizures is set to launch in the second quarter of 2020, after being designated Schedule V by the DEA.
from Front page feed https://ift.tt/3d0ehHI
from Front page feed https://ift.tt/3d0ehHI
Comments
Post a Comment